Fate Therapeutics Inc (FATE NASDAQ) stock market data APIs
$2.0167
0.06(3%)
as of November 2, 2026
Try our APIs with
free plan!
Fate Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.
Prev. Close
2.0167
Open
2.075
High
2.1621
Low
1.9696
52 wk Range
0.95-3.23
Market Cap
241 M
Shares Outstanding
120 M
Revenue
6 491 K
EPS
-0.25
Beta
2.666
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Fate Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Fate Therapeutics Inc data using free add-ons & libraries
Get Fate Therapeutics Inc Fundamental Data
Fate Therapeutics Inc Fundamental data includes:
- Net Revenue: 6 491 K
- EBITDA: -120 502 000
- Earnings Per Share: -1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-13
- EPS/Forecast: -0.28
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Fate Therapeutics Inc News
New
Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise
Entera Bio Ltd. Former Gilead and Amgen executive joins Entera with over 35 years of experience advancing and commercializing impactful and blockbuster therapies TEL AVIV, Israel, Oct. 06, 2026 (GLO...
Sector Update: Healthcare Stocks Edge Higher Premarket Friday
Healthcare stocks were edging higher premarket Friday, with the State Street Health Care Select Sect PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch.
You probably know Johnson & Johnson (NYSE: JNJ) mainly for its prescription medications. Some may be familiar with the company's medical devices. But J&J has another role that many people may not know...
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent...
Get Fate Therapeutics Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.